Global Still’sDisease Treatment Market, by Treatment (Pain Management, Corticosteroids,Tocilizumab, Canakinumab, Anakinra, and Others), by Route of Administration(Injectable and Oral), by Distribution Channel (Retail Pharmacies, HospitalPharmacies, and Online Pharmacies), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa), is estimated to bevalued at US$1,539.4 million in 2020 and is expected to exhibit a CAGR of 4.49%during the forecast period (2020-2027), as highlighted in a new report publishedby Coherent Market Insights.
Still’s disease is a raresystemic inflammatory condition classified under polygenic autoinflammatorydisorder. The condition is characterized by persistent high spiking fever,salmon colored skin rash, and arthralgia. Still’s disease is more commonlyobserved in infants, known as systemic-onset juvenile idiopathic arthritis(SOJIA) whereas, in adults, it is referred to as adult-onset Still’s disease(AOSD). However, there is no single diagnostic test available for Still’sdisease. Diagnosis is typically done based on the observation of aforementionedsymptoms. Also, the treatment option for this condition is selected based on thevarying degree of symptoms.
Players in the market are focusedon research & development, drug approvals, and launching them in themarket, which is driving growth of the still’s disease treatment market.Moreover, companies are focused on partnerships and joint agreements for thedevelopment of novel therapies. For instance, in May 2019, ChugaiPharmaceutical Co., Ltd. received expanded drug approval for adult-onsetStill's disease from the Ministry of Health Labor and Welfare in Japan forActemra (tocilizumab). Actemra is used for Still’s disease treatment.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/4023
Similarly, in April 2018, SwedishOrphan Biovitrum AB received expanded approval from the European Commission(EC) for Kineret (anakinra), which is an interleukin-1 receptor antagonist forthe treatment of Still’s Disease. Kineret was previously approved forrheumatoid arthritis treatment. This approval expanded indication of anakinraas well as addresses the significant unmet medical need among Still’s diseasepatient population. Such factors are expected to strongly support growth of thestill’s disease treatment market.
Still’s Disease Treatment Market- Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 outbreak has adverselyaffected the still’s disease treatment market growth. It has become difficultfor the researchers to conduct researches during this COVID-19 pandemic. Peoplewith Still's disease are at more risk to get infected with the COVID-19 virus.Therefore, key players in this industry are focusing on developing strategiesto help patients to remain agile during the global disruptions due to thepandemic crisis. Moreover, the government bodies of various countries aretaking initiatives to deal with the current chaos.
Browse 26 Market Data Tables and28 Figures spread through 140 Pages and in-depth TOC on Still’s DiseaseTreatment Market, By Treatment (Pain Management, Corticosteroids, Tocilizumab,Canakinumab, Anakinra, and Others), By Route of Administration (Injectable andOral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, andOnline Pharmacies), and By Region (North America, Latin America, Europe, AsiaPacific, Middle East, and Africa)- Forecast to 2027"
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/stills-disease-treatment-market-4023
The rise in funding for research& development to develop novel treatment and therapies is a major factorpropelling growth of the global still’s disease treatment market. Moreover, theemergence of drugs for the complications related to adult-onset still’s diseasetreatment is another factor boosting the market growth. For instance, in June2020, the U.S. Food and Drug Administration (FDA) approved the usage ofCanakinumab (Ilaris) in active still’s disease.
Key Takeaways of the Global Still’sDisease Treatment Market:
The global still’s diseasetreatment market is expected to exhibit a CAGR of 4.49% during the forecastperiod (2020-2027), owing to collaborations and drug launches by market players
Among therapy types,corticosteroid segment accounted for significant revenue share in the globalmarket. Corticosteroid therapy is started promptly with the dosage of 0.5–1mg/kg/day, once the diagnosis is confirmed.
Major players operating in theglobal still’s disease treatment market include AB2 Bio Ltd., Jubilant LifeSciences Ltd, F. Hoffmann-La Roche Ltd, Swedish Orphan Biovitrum AB, NovartisAG, Vintage Labs, Teva Pharmaceutical Industries Ltd, Hikma PharmaceuticalsPLC, Mylan N.V., Sun Pharmaceutical Industries Ltd, Horizon Therapeutics plc,Zydus Cadila, Dr Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, andFresenius Kabi AG.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/4023
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
